JP Morgan Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has downgraded Halozyme Therapeutics from Overweight to Neutral, while raising the price target from $52 to $57.
September 19, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan has downgraded Halozyme Therapeutics from Overweight to Neutral, indicating a more cautious outlook, but has raised the price target to $57, suggesting potential for moderate growth.
The downgrade from Overweight to Neutral suggests a less bullish outlook from JP Morgan, which could lead to a neutral short-term impact on the stock price. However, the raised price target to $57 indicates some confidence in potential growth, balancing the downgrade.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100